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Skeletal cryptococcosis, an aspect of disseminated cryptococcal disease or isolated
skeletal cryptococcal infection, is a rare but treatable disease. However, limited
information is available regarding its clinical features, treatment, and prognosis. This
systematic review examined all cases published between April 1977 and May 2013
with regard to the factors associated with this disease, including patient sex, age,
and epidemiological history; affected sites; clinical symptoms; underlying diseases;
laboratory tests; radiological manifestations; and delays in diagnosis, treatment, follow-up
assessments, and outcomes. We found that immune abnormality is a risk factor but does
not predict mortality; these observations are due to recent Cryptococcus neoformans var
gattii (CNVG) outbreaks (Chaturvedi and Chaturvedi, 2011). Dissemination was irrespective
of immune status and required combination therapy, and dissemination carried a worse
prognosis. Therefore, a database of skeletal cryptococcosis cases should be created.
Keywords: skeletal cryptococcosis, Cryptococcus neoformans, immune status, underlying disease, dissemination
INTRODUCTION
Cryptococcosis, formerly known as torulosis, European blasto-
mycosis, or Busse-Buschke disease, is caused by Cryptococcus
neoformans (C neoformans). This species was first isolated from
peach juice by Sanfelice in 1894 (Mitchell and Perfect, 1995; Jain
et al., 2013). Cryptococcus is a spherical-to-oval, encapsulated,
yeast-like fungus that is widespread in spoiled milk, soil, and
bird droppings, especially pigeon excreta. C neoformans can be
divided into Cryptococcus neoformans var neoformans (CNVN)
and Cryptococcus neoformans var gattii (CNVG), both of which
are pathogens in humans and animals. They were not consid-
ered different varieties until 1970, when CNVG was officially
suggested as a new species based on mounting evidence dis-
covered since the first CNVG report in 1896 (Speed and Dunt,
1995; Chaturvedi and Chaturvedi, 2011; Harris et al., 2011).
In addition, an on-going CNVG outbreak originated in 1999
and reappeared in 2004 (Chaturvedi and Chaturvedi, 2011). The
most affected organs are the lungs and central nervous sys-
tem, but virtually any organ (e.g., the skin, joints, eyes, urinary
tract, liver, prostate, myocardium, muscles, kidneys, and bone)
can be involved through lymphangitic and hematogenous spread
after inhaling fungal propagules. Skeletal cryptococcosis is rare.
Furthermore, this disease can be divided into two types: skeletal
cryptococcosis, which is an aspect of disseminated cryptococco-
sis, and primary skeletal cryptococcosis, which does not involve
other tissues (Chleboun and Nade, 1977; Behrman et al., 1990;
Wood and Miedzinski, 1996). Due to its low morbidity rate,
little is known about this disease. Moreover, its basic clinical
features, treatment, and prognosis have long perplexed clini-
cians. Serious consequences, including death, have occurred in
certain patients (Singh and Xess, 2010). Therefore, a systemati-
cal retrospective analysis of skeletal cryptococcosis is crucial for
understanding this disease. Unfortunately, however, almost all of
the current studies regarding this disease have been presented as
case reports (Ramkillawan et al., 2013; Zhou et al., 2013), which
provides little and indirect insight for understanding of skeletal
cryptococcosis. Thus, a systematic, retrospective analysis of all
published cases of skeletal cryptococcosis reported between April
1977 and the present time was conducted to clarify its clinical fea-
tures, treatments, and prognoses—all of which are critical issues
for fully understanding this disease. Importantly, treatment and
prognostic suggestions based on the analysis are provided.
MATERIALS AND METHODS
SEARCH STRATEGY AND SELECTION CRITERIA
A systematic online search was performed for cases reported
over a 36-year period from April 1977 to the present time
using PubMed, Medline, EBSCO, SpringerLink, Ovid, Highwire,
ProQuest, and Wiley InterScience. We applied the following
algorithm in both the medical subject heading (MeSH) and
the search field. The MeSH terms “case reports” and “review”
were combined with “Cryptococcus,” “Cryptococcus neoformans,”
“osteomyelitis,” or “immunocompromised host,” and theseMeSH
terms were exploded when appropriate. Search terms such as
“cryptococcosis,” “skeletal,” “bone,” “joints,” “skull,” “arthritis,”
“disseminated,” or “immunocompetent” were also combined
with the MeSH terms to increase the number of relevant arti-
cles retrieved. Google Scholar was also searched, and the citations
in each article were reviewed to identify additional references
that were not retrieved during the primary search. Language
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restrictions were not applied, and two researchers independently
conducted all searches.
“Disseminated skeletal cryptococcosis” was defined as an
infection that involves two or more non-contiguous bone sites
or an infection that involves one bone site associated with extra-
skeletal sites; patients with soft tissue collections or abscesses adja-
cent to the involved bone were excluded (Wood and Miedzinski,
1996). “Classically immunodeficient conditions” were considered
to include corticosteroid use, HIV infection, interleukin-2 defi-
ciency, and T cell defects (Speed and Dunt, 1995; Yu et al., 2012).
Patients with other underlying diseases that affect immune func-
tion, such as diabetes mellitus, tuberculosis and connective tis-
sue disorders, were considered relatively immunocompromised.
“Osteomyelitis” was defined based on a positive radiograph,
bone scan, or histopathology (Harris et al., 2011). “Relapse” was
defined as the recurrence of symptoms at the previous disease
site and the rediscovery of viable cryptococci from a previously
checked sterile body site after successful primary therapy (Perfect
et al., 2010).
DATA COLLECTION AND ANALYSIS
The following information was retrospectively reviewed: patient
sex, age, and epidemiological history; involved sites; clinical
symptoms; underlying diseases; laboratory tests; radiological
manifestations; and delays in diagnosis, treatment, follow-up
assessment, and outcomes. Outcome was recorded as either
response (i.e., resolution or improvement of all signs and symp-
toms, including microbiological and serological abnormalities
and radiographic changes due to infection) or failure (i.e., dete-
rioration of the patient’s condition based on clinical features
and radiographic abnormalities, ultimately resulting in death)
(Kontoyiannis et al., 2001).
All cases were epidemiologically and clinically analyzed. The
hosts were categorized as patients with immune abnormalities
(including classically immunodeficient and relatively immuno-
compromised status) or as immunocompetent.
STATISTICAL ANALYSES
Statistical analyses were performed using IBM SPSS 18.0 (IBM
Corporation, Armonk, NY, USA). All continuous data were
expressed as means ± standard deviations (means ± SDs),
and comparisons were performed using One-Way ANOVAs.
Categorical variables were compared using the χ2-test. All tests
were two-tailed, and p < 0.05 were considered significant.
RESULTS
In total, 80 articles (including one written in Spanish [case 50]
and 79 written in English) that described 89 patients were col-
lected and analyzed retrospectively (Table 1). Case 25 recorded
only the affected site (orbit) and treatment (amphotericin [AMB]
and ketoconazole); thus, this case was removed from the analysis
due to unknown immune status.
SEX AND AGE
Forty-four (of 88, 50.0%) males and 44 (of 88, 50.0%) females
were included. Their ages ranged from 16 months to 84 years
with a mean (±SD) of 39.9 years (±19.6; Figure 1). Relatively
immunocompromised hosts (n = 31, 48.8 ± 17.9 years) were
older than immunocompetent hosts (n = 32, 33.9 ± 19.7 years;
ANOVA, p = 0.002) and classically immunodeficient hosts (n =
25, 36.7 ± 18.5 years; ANOVA, p = 0.018); however, classically
immunodeficient hosts were approximately the same age as the
immunocompetent hosts (ANOVA, p = 0.587).
EPIDEMIOLOGICAL HISTORIES
Thirteen (of 88, 14.8%) patients had epidemiological histories
(Table 2). The epidemiological histories of the patients with
immune abnormalities (seven of 56, 12.5%) and those who were
immunocompetent (six of 32, 18.8%) did not significantly differ
(χ2-test, p = 0.629).
INVOLVED SITES
Regarding bone and joint infections, see Figures 2, 3A,B. Multiple
site infections did not differ among the classically immunodefi-
cient (10 of 25, 40.0%), relatively immunocompromised (13 of
29, 44.8%), and immunocompetent groups (10 of 32, 31.3%;
χ2-test, p = 0.542). Extra-skeletal cryptococcosis was found in
34 patients (Figure 3C). The patients categorized as classically
immunodeficient (16 of 25, 64.0%) were more likely to have
extra-skeletal infections than were those categorized as rela-
tively immunocompromised (10 of 31, 32.3%;χ2-test, p = 0.018)
and immunocompetent (eight of 32, 25.0%; χ2-test, p = 0.003),
whereas patients categorized as relatively immunocompromised
or immunocompetent did not differ in this regard (χ2-test;
p = 0.524). Excluding case 25, 42 (of 88, 47.7%) patients had
disseminated cryptococcosis. The patients categorized as clas-
sically immunodeficient (17 of 25, 68.0%) were more likely
to have disseminated cryptococcosis than were those catego-
rized as immunocompetent (11 of 32, 33.4%; χ2-test; p =
0.012). Dissemination among the patients categorized as clas-
sically immunodeficient did not differ from that among those
categorized as relatively immunocompromised (14 of 31, 45.2%;
χ2-test; p = 0.087), nor did the dissemination among the patients
categorized as relatively immunocompromised differ from
that among those categorized as immunocompetent (χ2-test;
p = 0.382).
CLINICAL SYMPTOMS
The predominant complaints included soft tissue swelling and
pain, the duration of which ranged from acute admission to 3
years. Of the evaluable 86 patients (excluding cases 25, 41, and 50
whose data were not available), fever was observed in 18 (20.9%)
patients, but body temperature measurements were only available
in 12 of these patients (66.7%) and ranged from 37.4◦C to 39.2◦C
(mean temperature = 38.35 ± 0.61◦C).
UNDERLYING DISEASES
Of the 88 patients (excluding case 25), 25 (28.4%) were catego-
rized as classically immunodeficient, 31 (35.2%) were relatively
immunocompromised, and 32 (36.7%) were immunocompetent.
Corticosteroid use (18 of 25, 72.0%) was the most common cause
of classically immunodeficient status. Diabetes mellitus (nine of
31, 29.0%) followed by tuberculosis (seven of 31, 22.6%) and
connective tissue disorders (five of 31, 16.1%) were themost com-
mon causes of the relatively immunocompromised status. Of the
32 patients in the immunocompetent group, 22 (68.8%) were
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FIGURE 1 | Pie chart of the 88 patients’ age.
described in articles published before 1999, and 10 (31.2%) were
described in articles published after 2004. No immuno-
competent patients were described between 1999 and
2004.
LABORATORY TESTS
The erythrocyte sedimentation rate (ESR) was documented for
40 (of 89, 44.9%) patients. Thirty-seven (of 40, 92.5%) ESRs were
elevated (i.e., >20mm/h for females and >15mm/h for males)
for 24 (of 37, 64.9%) female patients and 13 (of 37, 35.1%)
male patients. Among the 24 female patients, definite elevated
ESRs were documented in 23 (of 24, 95.8%) patients (average,
52.0mm/h ± 27.3), whereas among the 13 male patients, defi-
nite elevated ESRs were documented in 10 (of 13, 76.9%) patients
(average, 49.0mm/h ± 30.5).
The diagnostic specimens were most often obtained from
open biopsies, followed by aspiration and incision and drainage
(Table 3). All 67 cases with fungal cultures showed positive
results. Of the 53 histopathological analyses, the diagnostic spec-
imens were obtained from open biopsies in 37 (69.8%) cases,
aspiration in 13 (24.5%) cases, and incision and drainage in
three (5.7%) cases; positive results were obtained for 21 (of
37, 56.8%) cases, seven (of 13, 53.8%) cases, and one (of
three, 33.3%) case, respectively. Positive histopathological anal-
yses showed foreign-body giant cells and capsulated yeast-like
organisms. The capsule structure was stained using periodic acid
Schiff (PAS) stain in 22 (of 29, 75.9%) patients, mucicarmine
stain in 13 (of 29, 44.8%) patients, Gomori’s Methenamine
silver (GMS) stain in 18 (of 29, 62.1%) patients, Masson-
Fontana silver stain in case 15, and colloidal iron techniques in
case 23.
Only two patients with immunocompetent status (cases 44
and 82) had their strains successfully identified, using cultures
on dihydroxyphenylalanine (DOPA) and canavanine glycine bro-
mothymol (CGB) blue agars; both patients were infected with
CNVN.
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Table 2 | Epidemiological histories of 13 patients.
Case no./References Age/Sex Epidemiological histories Immune status
2/ Chleboun and Nade, 1977 40/F Contact with soil (farmer) Sarcoidosis
52/ Kumlin et al., 1997 79/M Contact with soil (farmer) Lymphopenia
56/ Case Records of the Massachusetts General
Hospital, 1999
55/M Contact with soil (farmer) Renal transplantation
82/ Corral et al., 2011 65/M Contact with soil (agricultural worker), chronic trauma
(1 year)
Immunocompetent
87/ Ramkillawan et al., 2013 56/M Contact with soil (agricultural worker) Immunocompetent
38/ Dounis et al., 1991 55/F Chronic trauma Immunocompetent
62/ Italiano et al., 2001 37/F Acute trauma Sjogren’s syndrome
68/ Wildstein et al., 2005 22/M Chronic trauma (4 weeks) Immunocompetent
26/ Zach and Penn, 1986 13/F Exposure to sea gull, chickens Immunocompetent
39/ Abdul-Karim et al., 1991 9/M Exposure to sparrows droppings Interleukin-2 deficiency
49/ Singh and Xess, 2010 49/M Exposure to pigeons Lymphopenia
60/ Prendiville et al., 2000 48/F Exposure to a parakeet Chronic sinusitis
85/ Jacobson et al., 2012 27/M Exposure to bird droppings Immunocompetent
RADIOLOGICAL MANIFESTATIONS
Of the 89 patients, 77 (86.5%) had one or more radiological
examinations of their affected bones. Sclerosis was observed in the
relatively immunocompromised cases 23 and 45; periosteal reac-
tion was described in 13 (of 76, 17.1%) patients. Subperiosteal
new bone formation was noted in case 79 (immunocompe-
tent), and irregular cortical destruction and extensive periosteal
reaction was noted in case 59 (relatively immunocompromised).
Of the 80 evaluable patients, osteomyelitis was found in 51
(63.8%) patients. Case 41 was documented as having osteomyeli-
tis, and the other 50 patients were diagnosed based on either a
positive radiograph or bone scan; five (of 50, 10.0%) patients were
also diagnosed based on a positive histopathology. The presence
of osteomyelitis among patients categorized as classically immun-
odeficient (11 of 18, 61.1%), relatively immunocompromised (20
of 30, 66.7%), and immunocompetent (20 of 32, 62.5%) did not
differ (χ2-test; p = 0.911).
DELAYS IN DIAGNOSIS
Of the 88 evaluable patients (excluding case 36, that was diag-
nosed post-mortem), delays in diagnosis occurred among 20 (of
88, 22.7%) patients. The delayed time of these 20 patients (doc-
umented in only 14 patients) ranged from 6 days to 10 months.
In addition, 13 (of 20, 65.0%) patients were initially misdiagnosed
(Table 4), most commonly with tuberculosis (6 of 13, 46.2%) pri-
marily occurring in the vertebrae (5 of 6, 83.4%). The location of
the source of discomfort was not reported for the remaining 7 (of
20, 35.0%) patients.
TREATMENT, FOLLOW-UP ASSESSMENT, AND OUTCOMES
Of the evaluable 87 patients (excluding patient 36 who did
not receive any treatment and was diagnosed at autopsy as
well as patient 59 whose treatment information was not
available), 80 (of 87, 92.0%) patients received one treatment
regimen and the other 7 (of 87, 8.0%) patients changed
treatments because their symptoms became aggravated or
recurred.
Of the 80 patients who received only one treatment regimen,
3 (of 80, 3.8%) patients received surgery alone, 32 (of 80, 40.0%)
patients received medical treatment alone and 45 (of 80, 56.2%)
patients received surgery in conjunction with medical treatment.
Of the 3 patients that underwent surgery alone, 1 (of 3, 33.3%)
patient died and 2 (of 3, 66.7%) patients responded. Of the
32 patients treated with medical treatment alone, 10 patients
(31.3%) received monotherapy (AMB was the most commonly
used treatment; 5 of 10, 50.0%) and three patients (30.0%) died.
Twenty-two (of 32, 68.7%) patients received combined therapies
(AMB plus 5-FC was the most commonly used treatment; 14
of 22, 36.4%), three of whom died (13.6%). Of the 45 patients
treated with surgery and medical treatments, 18 patients (40.0%)
underwent surgery and monotherapy (AMBwas most commonly
used; 10 of 18, 55.6%), one of whom died (5.6%). A total of 27
(of 45, 60.0%) patients underwent surgery combined with sev-
eral medicines (AMB plus 5-FU was the most commonly used
treatment; 11 of 27, 40.7%), four of whom died (14.8%).
In total, 68 patients responded to treatment, and 12 patients
died (Table 5). Improvements of the symptoms and the rclini-
cal signs of all 68 patients who responded were observed. Only
six of these patients’ (8.8%) ESRs were measured after treatment,
all of which were normal or decreased. Only 13 (of 68, 19.1%)
patients underwent serum cryptococcal antigen testing, and all of
these patients showed reductions or undetectable levels. X-rays,
CT, or MRI scans were obtained in 21 (of 68, 30.9%) patients,
and all of them showed healing or resolution. Bone scans were
performed in two (of 68, 2.9%) patients, and both of them pre-
sented reduced isotope uptake. Six of the 12 patients who received
treatment but died were classically immunodeficient (50.0%), five
were relatively immunocompromised (41.7%), and case 4 was
immunocompetent (Table 6). In addition, nine (of 12, 75.0%)
patients presented with disseminated cryptococcosis. Only one of
12 patients’ deaths was directly caused by cryptococcosis (8.3%;
case 65, relatively immunocompromised).
Of the seven patients who changed treatment, symptom
aggravation during primary treatment occurred among five (of
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FIGURE 2 | Bones and joints involved (147 sites) in skeletal cryptococcal lesions.
seven, 71.4%) patients, one of whom (case 22, relatively immuno-
compromised) underwent an ESR examination that revealed an
ESR increase from 30mm/h to >80mm/h after the administra-
tion of 917mg of AMB for 14 weeks. Symptoms recurred for case
7 (immunocompetent) and case 60 (relatively immunocompro-
mised) after primary treatment, but neither met the criteria for
relapse. Of these seven patients, one case (case 58) was categorized
as classically immunodeficient, two were categorized as relatively
immunocompromised, and the other four (57.1%) were cate-
gorized as immunocompetent. Three (of seven, 42.9%) patients
presented with dissemination. All seven patients responded well
to the subsequent treatment.
The follow-up time ranged between 2 weeks and 15 years
(median = 13.5 months); half of all patients (30 of 60) were
followed-up for less than 1 year, and the other half were followed-
up for more than 1 year.
The factors associated with the overall skeletal cryptococco-
sis mortality rate, stratified by response to treatment, are listed
in Table 7. Dissemination was a risk factor the overall mortality
rate (p = 0.041); the patient immune status was not a risk factor
mortality (p = 0.056).
Finally, to compare the mortality rates associated with differ-
ent treatments, we analyzed 40 patients who were treated with
AMB alone (2 of 5, 40.0%), AMB plus 5-FC (11 of 14, 78.6%),
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FIGURE 3 | Pie chart of patients’ involved bones (A), joints (B) and extra-skeletal sites (C): 123, 24, 34, respectively.
Table 3 | Diagnostic modalities in 82 patients with skeletal
cryptococcosis.
Modality No. of Culture n (%) Histopathological Both n (%)
tests analysis n (%)
Open biopsy 50 13 (26.0) 10 (20.0) 27 (54.0)
Aspiration 27 14 (51.9) 5 (18.5) 8 (29.6)
Incision and
drainage
5 2 (40.0) 0 (0) 3 (60/0)
Total No. 82 29 (35.4) 15 (18.3) 38 (46.3)
surgery combined with AMB (9 of 10, 90.0%), or surgery com-
bined with AMB plus 5-FC (8 of 11, 72.7%); these cases were
chosen because these three treatments (AMB, 5-FC and surgery)
were utilized more often than other therapies. Specific informa-
tion is listed in Table 8. The mortality rates of the four treatment
regimens did not differ (p = 0.229), and dissemination predicted
mortality (p = 0.044).
DISCUSSION
Because knowledge regarding the clinical features, treatment, and
prognosis of skeletal cryptococcosis is limited, this large-scale sys-
tematic analysis of previously reported skeletal cryptococcosis was
conducted to better understand the disease.
Skeletal cryptococcosis affects both individuals who are
immunocompetent and those with abnormal immunity
(Behrman et al., 1990; Zhang et al., 2012). Our study revealed
immune status to be an important risk factor for this infec-
tion, which is consistent with previous reports (Hawkins and
Armstrong, 1984; Jacobson et al., 2012). Most of the patients
with immune abnormalities included in this study had defects of
cellular immunity such as those related to lymphoma, leukemia,
sarcoidosis, and long-term steroid use. Cellular immunity defects
might predispose patients to cryptococcal infection, which can
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Table 5 | Treatment of the 80 patients.
Treatment Definite medical therapy No. of patients Outcome
Response n (%) Failure n (%)
Surgery (n = 3) 3 2 (66.7) 1 (33.3)
Medical treatment (n = 32) AMB 5 2 (40.0) 3 (60.0)
AMB+5-FC 14 11 (78.6) 3 (21.4)
Flu 5 5 (100.0) 0 (0)
AMB+Flu 2 2 (100.0) 0 (0)
AMB+itraconazole 1 1 (100.0) 0 (0)
AMB+5-FC+Flu 2 2 (100.0) 0 (0)
AMB+ketoconazole 1 1 (100.0) 0 (0)
AMB+5-FC+ketoconazole 1 1 (100.0) 0 (0)
AMB+5-FC+Flu+itraconazole 1 1 (100.0) 0 (0)
32 26 (81.2) 6 (18.8)
Surgery and medical treatment (n = 45) AMB 10 9 (90.0) 1 (10.0)
AMB+5-FC 11 8 (72.7) 3 (27.3)
Flu 6 6 (100.0) 0 (0)
AMB+Flu 8 8 (100.0) 0 (0)
AMB+5-FC+Flu 5 4 (80.0) 1 (20.0)
Ketoconazole 2 2 (100.0) 0 (0)
AMB+ketoconazole 1 1 (100.0) 0 (0)
AMB+5-FC+ketoconazole 1 1 (100.0) 0 (0)
AMB+Flu+itraconazole 1 1 (100.0) 0 (0)
45 40 (88.9) 5 (11.1)
Total No. 80 68 (85.0) 12 (15.0)
AMB, amphotericin B; 5-FC, 5-fluorocytosine; Flu, fluconazole.
lead to T cell abnormalities in hosts without other underlying
diseases. This possibility suggests that T cell mediated immunity
is the primary pathway for preventing cryptococcal infections
(Meredith et al., 1979; Agadi et al., 2010; Jacobson et al., 2012).
Thus, once a patient is suspected with cryptococcal infection,
the evaluation of lymphocyte subsets, including counts and
stimulation studies, should be routinely performed to specifically
and sensitively reveal the patient immune status, as suggested by
Wood and Miedzinski (1996).
Since the introduction of highly active antiretroviral ther-
apy (HAART) in 1995, the mortality rate associated with
AIDS has dramatically decreased (Mitchell and Perfect, 1995).
Subsequently, steroids are considered the leading cause of skeletal
cryptococcosis because of their extensive use for both therapeu-
tic and recreational purposes (Benard et al., 1996; Hummel et al.,
1996). In addition, the incidence of chronic diseases such as dia-
betes mellitus and hypertension has increased (Jain et al., 1999;
Witte et al., 2000; Bruno et al., 2002). The number of patients
with cryptococcal disease and who are classified as immunocom-
petent has risen greatly since 2004 and is estimated to increase
by 0.2 per million every year (Zhang et al., 2012; Jain et al.,
2013; Zhou et al., 2013). This increase was most likely due to
the CNVG outbreak that originated in 1999 and resurged in
2004 (Chaturvedi and Chaturvedi, 2011). However, determin-
ing the reasons why patients with immunocompetent statuses
were not found between 1999 and 2004 is difficult. CNVN,
which is ecologically widespread and exists in soil contaminated
by pigeon excreta, is more common in immunocompromised
patients with cell-mediated immune deficiencies, whereas CNVG,
which is traditionally found in eucalyptus trees located in trop-
ical and subtropical areas (Speed and Dunt, 1995; Chaturvedi
and Chaturvedi, 2011; Harris et al., 2011) (the south-eastern
region of China is the most common location (Chen et al.,
2008; Negroni, 2012), affects immunocompetent hosts. Thus, it
is essential for clinical microbiology laboratories to accurately
differentiate CNVG from other forms of C neoformans to deter-
mine the final diagnosis and guide the initiation of or institute
the appropriate treatment (Klein et al., 2009; Singh and Xess,
2010). Recently, a testing survey conducted by the New York
State Department of Health indicated that only 5.0% of clinical
laboratories were able to correctly identify CNVG (Klein et al.,
2009). CNVN and CNVG are commonly differentiated by DOPA
agar and CGB agar, where different colored reactions can be
observed (Klein et al., 2009; Qadir et al., 2011). The results are
often available within 48 h; CNVG produces a blue color, whereas
CNVN fails to cause a color change. Furthermore, Klein and
colleagues first used the specific method of D2 large ribosomal
subunit region sequencing to identify CNVG (Klein et al., 2009).
McTaggart and colleagues explored a cost-effective method called
matrix-assisted laser desorption/ionization time-of-flight mass
spectrometry (MALDI-TOF MS) (McTaggart et al., 2011). Feng
X provided a rapid, simple, and reliable method using Singleplex
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Table 6 | Twelve deceased patients.
Case no./References Age/Sex Disseminated
or not
Immune status Treatment Cause of death
1/ Chleboun and Nade, 1977 43/M No Relatively immunocompromised Surgery Unknown
4/ Chleboun and Nade, 1977 15/M No Immunocompetent AMB395mg Tuberculous
hepatitis and
staphylococcal
pneumonia
12/ Heenan and Dawkins, 1981 54/M Yes Classically immunodeficient Surgery AMB+5-FC2700g Unknown
16/ Cash and Goodman, 1983 59/M CNS Relatively immunocompromised AMB+5-FC Cardiorespiratory
arrest on the
13th day of
therapy
17/ Perfect et al., 1983 46/F CNS, skin,
blood
Classically immunodeficient AMB+5-FC Serratia
septicemia
18/ Perfect et al., 1983 32/F Retina, CNS,
urine, blood
Classically immunodeficient AMB Unknown
21/ Reinig et al., 1984 10/F No Classically immunodeficient Surgery AMB+5-FC Respiratory
failure
27/ Ricciardi et al., 1986 37/M CNS, skin,
blood
Classically immunodeficient AMB+5-FC Unknown
54/ Liu, 1998 60/M Yes Relatively immunocompromised Surgery AMB Severe hepatic
failure
65/ Gupta et al., 2003 24/F Yes Relatively immunocompromised Surgery AMB+5-FC Cryptococcosis
70/ Goldshteyn et al., 2006 84/F CNS Classically immunodeficient Surgery×2 AMB+5-FC+Flu Unknown
77/ Agadi et al., 2010 29/F Yes Relatively immunocompromised AMB Cardiac failure
AMB, amphotericin B; 5-FC, 5-fluorocytosine; Flu, fluconazole.
Table 7 | Factors associated with overall skeletal cryptococcosis
mortality (excluding cases 25, 36, and 59 and the 12 deceased
patients).
Characteristics Non-survival (%) Survival (%) P-value
N 67 12
Mean age 39.2 ± 19.1 41.1 ± 21.1 0.752
No. Male 33 (49.3%) 5 (41.7%) 0.628
Epidemiological histories 11 (16.4%) 0 (0) 0.289
Multiple site infections 23 (34.3%) 6 (50.0%) 0.476
Extra-skeletal infections 25 (37.3%) 6 (50.0%) 0.612
Dissemination 28 (41.8%) 9 (75.0%) 0.034
Immune abnormality 40 (59.7%) 11 (91.7%) 0.071
Delay in diagnosis 14 (20.9%) 3 (25.0%) 1.000
PCR assay that is suitable for laboratory diagnoses and large-
scale epidemiologic studies (Feng et al., 2013). Both strains were
shown to have similar susceptibilities to antifungal drugs when
tested in vitro in some reports (Chen et al., 2000; Thompson et al.,
2009). The treatments for patients with disseminated disease due
to CNVG are the same as those for CNVN.
Our study did not reveal a relationship between diagnosis and
sex, which is consistent with previous reports (Behrman et al.,
1990; Wood and Miedzinski, 1996; Zhou et al., 2013). However,
Behrman and colleagues reported that 51.0% (20 of 39) patients
were males in 1990 (Behrman et al., 1990), whereas Bruno and
colleagues reported that 61.9% (13 of 21) patients were males
Table 8 | Factors associated with 40 patients treated with AMB alone,
AMB plus 5-FU, surgery combined with AMB, or surgery combined
with AMB plus 5-FU.
Characteristics Non-survival (%) Survival (%) P-value
N 30 10
Mean age 36.2 ± 22.4 36.6 ± 17.8 0.964
No. Male 16 (53.3%) 4 (40.0%) 0.465
Epidemiological histories 5 (16.7%) 0 (0) 0.408
Multiple site infections 8 (26.7%) 6 (60.0%) 0.126
Extra-skeletal infections 11 (36.7%) 5 (50.0%) 0.709
Dissemination 11 (36.7%) 8 (80.0%) 0.044
Immune abnormality 16 (53.3%) 9 (90.0%) 0.090
Delay in diagnosis 7 (23.3%) 3 (30.0%) 1.000
Treatment AMB 2 (6.7%) 3 (30.0%) 0.229
AMB+5-FC 11 (36.7%) 3 (30.0%)
surgery+AMB 9 (30.0%) 1 (10.0%)
surgery+AMB+5-FC 8 (26.7%) 3 (30.0%)
in 2002 (Bruno et al., 2002); these findings might be due to the
smaller number of reviewed cases in their studies. Cryptococcal
infections occurred in all age groups, with a slight tendency
toward for younger people to be affected (e.g., most patients
were under 45 years of age). However, the patients with rela-
tively immunocompromised statuses were elderly, which might
be explained by the aforementioned leading cause of skeletal
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cryptococcosis (CNVN) and the fact that older patients are more
likely to have chronic diseases.
Skeletal cryptococcosis is usually secondary to hematogenous
migration from a primary pulmonary infection after inhaling
microscopic, airborne fungal spores (especially after exposure
to soil or poultry). These spores are a cause for cryptococcal
infection (Armonda et al., 1993; Wood and Miedzinski, 1996).
Direct inoculation during trauma is also possible (Chleboun and
Nade, 1977; Dounis et al., 1991; Italiano et al., 2001). However,
only 14.8% of the patients included in this review had contact
with soil or pigeons or a history of trauma; incomplete patient
histories might explain this finding. In addition, host immu-
nity did not significantly affect their epidemiological histories.
This result differs from that of Jacobson and colleagues, who
reported that host immunity effectively excluded infection after
initial exposure (Jacobson et al., 2012). This disparity might be
due to the recent increase in patients with immunocompetent
statuses. Other infectious pathways include direct inoculation
through the skin during trauma and contiguous spread combined
with the lower involvement of the lymphatic route (Zanelli et al.,
2001).
Compared with most of the previous articles that reviewed
skull cryptococcosis, articular cryptococcosis, or other bony cryp-
tococcosis alone, such as in Chleboun and Nade’s (1977) study,
we examined all types of involved sites (Chleboun and Nade,
1977). Any bone or joint can be affected, but the most com-
mon site was the vertebrae, which is consistent with Chleboun’s
report (Chleboun and Nade, 1977); the sufficient blood supply
of the vertebrae might explain this finding. The second and third
most common sites have changed from the pelvis and rib in 1977
to the skull and femur (Chleboun and Nade, 1977). The most
common affected joint was the knee, which is consistent with
the study by Bruno et al. (2002). The involvement of multiple
bones occurred more regularly in adjacent areas than discrete
areas, which indicates the extension of local foci; this result is con-
sistent with Behrman and colleagues’ study in 1990 (Behrman
et al., 1990). Patients with classically immunodeficient statuses
were most likely to have concurrent extra-skeletal involvement
sites, and meningitis was the most common extra-skeletal infec-
tion. Overall, 47.7% of patients with (especially the classically
immunodeficient status) or without immune abnormalities pre-
sented with dissemination, and these patients were more likely to
show symptom aggravation, recurrence, or death.
The characteristic symptoms of skeletal cryptococcosis are
pain and swelling (Chleboun and Nade, 1977; Behrman et al.,
1990; Wood and Miedzinski, 1996). Fever, which is not a pri-
mary patient complaint (Behrman et al., 1990), was found in
only 20.9% of evaluable patients comparable with a previous
study, which reported a rate of 18.0% (Wood and Miedzinski,
1996). In addition, classic symptoms such as vomiting (Cash
and Goodman, 1983; Agadi et al., 2010), blurred vision (Cash
and Goodman, 1983; Prendiville et al., 2000; Ching et al., 2004),
dizziness, seizure, diplopia, trismus (Cash and Goodman, 1983),
limited motion (Bunning and Barth, 1984; Ricciardi et al., 1986;
Sinnott and Holt, 1989), paralysis (Meredith et al., 1979; Gupta
et al., 2003), muscle weakness, urinary retention (Gurevitz et al.,
1994), and sciatica (Houda et al., 2011)can occur among patients
with cryptococcal infections of specific sites; the location can
assist in making the final diagnosis.
The ESR can be elevated to various levels when the infection
is found in the bone, decline to normal when osseous lesions
heal, and increase again when patients have an extensive relapse
(Chleboun and Nade, 1977; Behrman et al., 1990; Wood and
Miedzinski, 1996).
The diagnosis of skeletal cryptococcosis is primarily based on
the examination of lesion specimens from aspiration, surgery,
and open biopsies (Behrman et al., 1990; Wood and Miedzinski,
1996; Gupta et al., 2003). Aspiration was the most common
method performed in our review, whereas Behrman and col-
leagues reported that open biopsy was the most commonly per-
formed technique (Behrman et al., 1990); this discrepancy might
be attributable to advancements in medical techniques since
1990. All of these methods have a similar diagnostic value. Thus,
aspiration is recommended first given its increased convenience
and minimal harm caused to the body; however, if aspiration
specimens fail to yield diagnostic value, then open biopsy is rec-
ommended. All samples should be sent for culture, smear, and
histology examinations (Wood and Miedzinski, 1996). Culture is
the gold standard diagnosis (Wood and Miedzinski, 1996). After
staining with India ink, the organism resembles cells with a halo
due to a lack of capsule staining, and it is easily detected using
specific PAS, mucicarmine, and GMS stains (although it is poorly
stained by H & E). Urease-positive mucoid colonies are produced
in cultures on SDA agar usually within 3–5 days (Mitchell and
Perfect, 1995; Qadir et al., 2011; Jain et al., 2013). Currently avail-
able commercial methods for yeast identification, such as API
20 AUX (bioMerieux, Paris, France) and Vitek (bioMerieux), are
used to identify the yeast-like organisms (Qadir et al., 2011; Zhou
et al., 2013). Once the organisms are detected, identifying the
strain is recommended as mentioned above.
Examinations for disseminated cryptococcosis should be per-
formed after identification. Relevant examinations generally con-
sist of the following procedures: lumbar puncture for antigen
testing and culture, blood culture, urine culture, sputum culture,
and skin lesion culture (Wood and Miedzinski, 1996). Recently, a
marrow aspirate was considered in the diagnosis of disseminated
cryptococcosis (Venkatachala et al., 2010). Testing for serum
cryptococcal antigen using a latex agglutination test (LA), an
enzyme immunoassay (EIA) or lateral flow assay (LFA) is useful
for diagnosis given their sensitivity and specificity (Bruno et al.,
2002; Lindsley et al., 2011; Hansen et al., 2013). However, serum
cryptococcal antigen is not always positive even when infection
is demonstrated via culture (Hawkins and Flaherty, 2007). CSF
cryptococcal antigen testing is more highly sensitive and specific
for meningitis than serum cryptococcal antigen testing (Hawkins
and Flaherty, 2007).
The radiological findings of skeletal cryptococcus were non-
specific (Chleboun and Nade, 1977; Behrman et al., 1990; Wood
and Miedzinski, 1996); sclerosis or periosteal reaction, which are
typical symptoms associated with tumors, were found in our
study (Levine et al., 1985; Bosch et al., 1994; Witte et al., 2000;
McGuire et al., 2011). Furthermore, patients with poor immune
status were less likely to show radiological features of malignancy.
The differential diagnoses based on radiological features included
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microbial infections, namely Staphylococcus aureus, Brucella,
Actinomyces, tuberculosis, and neoplasms such as Ewing’s sar-
coma, osteogenic sarcoma, enchondroma, and giant cell tumor
(Behrman et al., 1990; Witte et al., 2000). In addition, the diag-
nosis of osteomyelitis is commonly indicated based on radio-
logical studies that are non-specific for C neoformans (Behrman
et al., 1990), and our results showed that patients can contract
osteomyelitis regardless of the presence of immune abnormalities.
Radiological studies should be routinely performed because they
assist the final diagnosis and can be used as a monitoring index to
detect the efficacy of therapy based on radiological improvement,
healing, or resolution.
The insidious course of this disease contributes to the delays
in diagnosis (Bunning and Barth, 1984; Matsushita and Suzuki,
1985; Baldwin et al., 1988). Importantly, tuberculosis was the
most common reason for misdiagnosis. Although our results
indicated that delayed diagnosis did not contribute to a worse sur-
vival rate, clinicians must be alerted to this disease and identify it
in a timely manner.
Except for the lungs ans CNS, no standardized treatment pro-
tocol exists for cryptococcal infection for specific body sites (Jain
et al., 2013; Ramkillawan et al., 2013). For these sites, surgery
in conjunction with antifungals, antifungals alone, or (rarely)
surgery alone have been demonstrated to be effective. According
to the Infectious Disease Society of America (IDSA), surgery,
which effectively and rapidly eliminates the fungal burden and
prevents the contiguous spread of infection (Chleboun and Nade,
1977; Govender et al., 1988; McGuire et al., 2011), should be
performed to patients with persistent or refractory bone disease
(Perfect et al., 2010). Surgery also provides physicians with the
opportunity to obtain specimens for histological and microbio-
logical examination to make a definitive diagnosis (Ramkillawan
et al., 2013). The selection of antifungal agents and the dura-
tion of therapy depends on factors including disease severity,
host immune status, the infection site, and therapeutic response
(Qadir et al., 2011; Zhang et al., 2012). Systemic therapy consists
of AMB, 5-FC, fluconazole, ketoconazole, or some combination
therein (Bryan, 1977; Galloway and Schochet, 1981; Stead et al.,
1988; Ueda et al., 1992; Perfect et al., 2010). Although, combina-
tion therapy with AMB and 5-FC (with or without surgery) did
not outperform AMB alone (with or without surgery) in terms
of improving the mortality rate (which might be due to the small
number of cases), combined therapy is recommended. This result
is contrary to previous reports (Bryan, 1977; Poliner et al., 1979;
Shaff et al., 1982; Raftopoulos et al., 1998; Perfect et al., 2010) and
might be due to the small number of cases reviewed here. Thus,
combined therapy is recommended given the prevention of sec-
ondary drug resistance, the shorter duration of therapy, smaller
total dosage, and the reduced likelihood of side effects (Bryan,
1977; Raftopoulos et al., 1998; Jain et al., 2011). The most com-
mon treatment is a combination of AMB and 5-FC, which can
decrease the high nephro- and hepatotoxicity of AMB (Bruno
et al., 2002). The lipid formulation of AMB is used in patients
with renal impairments (Perfect et al., 2010). The IDSA indicates
that 200-400mg per day of oral fluconazole for 6–12months is the
treatment of choice for patients with immunocompetent status
and non-meningeal, non-pulmonary cryptococcosis because of
its significantly reduced toxicity (Agadi et al., 2010; Perfect et al.,
2010; Qadir et al., 2011; Zhou et al., 2013). Several case reports
published over the last decade have demonstrated the successful
treatment of cryptococcal osteomyelitis using fluconazole alone
(Hummel et al., 1996; Wildstein et al., 2005; Agadi et al., 2010;
Qadir et al., 2011; Zhou et al., 2013). Patients with disseminated
cryptococcosis had unfavorable outcomes in our study, and this
result is consistent with previous reports (Behrman et al., 1990;
Bruno et al., 2002; Hawkins and Flaherty, 2007). Combination
induction therapy of AMB and 5-FC followed by consolidation
and maintenance therapies with fluconazole are recommended
for patients with disseminated cryptococcosis (Perfect et al., 2010;
Zhang et al., 2012). Suppressive treatments for disseminated dis-
ease due to CNVG are the same as those for CNVN described
above. The ultimate duration of therapy is unknown, but it
should be based on clinical findings, ESRs, serum cryptococcal
antigen levels, and radiological improvements (Goldshteyn et al.,
2006; Zhang et al., 2012).
The outcomes of patients with disseminated cryptococcosis
were unfavorable, and those of patients with or without immune
abnormalities were similar; these findings differ from previous
studies (Corral et al., 2011; Jou et al., 2011; Qadir et al., 2011;
Jain et al., 2013). This disparity might be explained by the recent
CNVG outbreak. The recurrence rate of skeletal cryptococcosis is
low (Hawkins and Flaherty, 2007). However, unlike the successful
treatment of cryptococcal meningoencephalitis (demonstrated
via CSF culture) and that of pulmonary cryptococcosis (demon-
strated via sputum culture or the specimens obtained during
bronchoscopy) (Perfect et al., 2010), it is difficult to prove the
success of primary therapy in skeletal cryptococcus. Hence, once
cannot distinguish relapse from recurrence. Clinical and radio-
graphical follow-up assessments, as well as serum cryptococcal
antigens, should be monitored carefully. For the qualitative or
quantitative detection of serum cryptococcal antigen, a latex
agglutination test (LA), an enzyme immunoassay (EIA) or a LFA
should be used, and LFA shows excellent overall agreement with
EIA (Lindsley et al., 2011; Hansen et al., 2013).Once an abnormal
manifestation occurs during the primary therapy, a larger total
dosage is recommended. If the abnormal manifestation recurs,
then susceptibility testing should be performed to formulate the
best therapy by evaluating the changes in theminimum inhibitory
concentration (MIC) of the recurrent isolates and original isolates
(Perfect et al., 2010). Prednisone prescribed for other diseases
should be tapered during skeletal cryptococcosis treatment, given
the drug’s effect on immunity (Noh et al., 1999).
CONCLUDING REMARKS
Skeletal cryptococcosis occurs in patients with immune abnor-
malities and even in those who are immunocompetent. An
immune abnormality is a risk factor but it does not predict
mortality. Likewise, neither immunocompetence nor immune
abnormalities predicted the deaths caused by recent CNVG out-
breaks. Patients with (especially classic immunodeficiencies) or
without immune abnormalities present with dissemination, and
these patients are more likely to have unfavorable prognoses.
Clinicians must be alert to this disease and be able to identify
the particular fungal strain. No standardized treatment protocol
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exists for skeletal cryptococcosis. Although, combination therapy
with AMB and 5-FC (with or without surgery) did not outper-
form AMB alone (with or without surgery) in terms of improving
the mortality rate (which might be due to the small number of
cases reported), combined therapy is recommended. Given that
our series was unable to collect all information (which led to
difficulties in further elucidating this disease), creating a disease
database of skeletal cryptococcosis is recommended.
AUTHOR CONTRIBUTIONS
Heng-Xing Zhou and Lu Lu, as first coauthors, contributed
equally to drafting and revising the review with input from all
authors. All authors approved the final version.
ACKNOWLEDGMENTS
The authors are grateful to Dr. Xiaohong Kong for critically
reading the manuscript and helpful discussions.
REFERENCES
Abdul-Karim, F. W., Pathria, M. N., Heller, J. G., and Sorensen, R. U. (1991). Case
report 664. Cryptococcus neoformans osteomyelitis. Skeletal Radiol. 20, 227–229.
doi: 10.1007/BF00241676
Agadi, J. B., Madni, N. A., Nanjappa, V., and Govindaiah, H. K. (2010).
Cryptococcal osteomyelitis of the skull in a patient with transient lymphopenia.
Neurol. India 58, 300–302. doi: 10.4103/0028-3886.63798
Al-Tawfiq, J. A., and Ghandour, J. (2007). Cryptococcus neoformans abscess and
osteomyelitis in an immunocompetent patient with tuberculous lymphadenitis.
Infection 35, 377–382. doi: 10.1007/s15010-007-6109-9
Amenta, P. S., Stead, J., and Kricun, M. E. (1983). Case report 226: isolated
Cryptococcus neoformans osteomyelitis of femur. Skeletal Radiol. 9, 263–265. doi:
10.1007/BF00354129
Amit, A., Sudish, K., and Pople, I. K. (2008). Primary calvarial cryptococcal
osteomyelitis in a patient with idiopathic lymphopenia. Acta Neurochir. (Wien)
150, 713–714. doi: 10.1007/s00701-008-1608-8
Armonda, R. A., Fleckenstein, J. M., Brandvold, B., and Ondra, S. L. (1993).
Cryptococcal skull infection: a case report with review of the literature.
Neurosurgery 32, 1034–1036. doi: 10.1227/00006123-199306000-00028
Baldwin, S., Stagno, S., Odrezin, G. T., Kelly, D. R., and Whitley, R. J. (1988).
Isolated Cryptococcus neoformans osteomyelitis in an immunocompetent child.
Pediatr. Infect. Dis. J. 7, 289–292. doi: 10.1097/00006454-198804000-00011
Behrman, R. E., Masci, J. R., and Nicholas, P. (1990). Cryptococcal skeletal infec-
tions: case report and review. Rev. Infect. Dis. 12, 181–190. doi: 10.1093/clin-
ids/12.2.181
Benard, G., Gryschek, R. C., Duarte, A. J., and Shikanai-Yasuda, M. A. (1996).
Cryptococcosis as an opportunistic infection in immunodeficiency secondary to
paracoccidioidomycosis. Mycopathologia 133, 65–69. doi: 10.1007/BF00439115
Bosch, X., Ramón, R., Font, J., Alemany, X., and Coca, A. (1994). Bilateral
cryptococcosis of the hip. A case report. J. Bone. Joint. Surg. Am. 76, 1234–1238.
Brand, C., Warren, R., Luxton, M., and Barraclough, D. (1985). Cryptococcal
sacroiliitis. Ann. Rheum. Dis. 44, 126–127. doi: 10.1136/ard.44.2.126
Bruno, K. M., Farhoomand, L., Libman, B. S., Pappas, C. N., and Landry, F.
J. (2002). Cryptococcal arthritis, tendinitis, tenosynovitis, and carpal tunnel
syndrome: report of a case and review of the literature. Arthritis Rheum. 47,
104–108. doi: 10.1002/art1.10249
Bryan, C. S. (1977). Vertebral osteomyelitis due to Cryptococcus neoformans. Case
report. J. Bone Joint Surg. Am. 59, 275–276.
Bunning, R. D., and Barth, W. F. (1984). Cryptococcal arthritis and cellulitis. Ann.
Rheum. Dis. 43, 508–510. doi: 10.1136/ard.43.3.508
Burton, R., Gogela, N., Rebe, K., McNally, M., and Meintjes, G. (2009).
Cryptococcal immune reconstitution inflammatory syndrome presenting with
erosive bone lesions, arthritis and subcutaneous abscesses. AIDS 23, 2371–2373.
doi: 10.1097/QAD.0b013e328330975f
Case Records of the Massachusetts General Hospital. (1999). Weekly
Clinicopathological Exercises. Case 19–1999, A 55-year-old man with a
destructive bone lesion 17 months after liver transplantation. New. Engl. J. Med.
340, 1981–1988. doi: 10.1056/NEJM199906243402508
Cash, J. B., and Goodman, N. L. (1983). Cryptococcal infection of the tem-
poral bone. Diagn. Microbiol. Infect. Dis. 1, 257–260. doi: 10.1016/0732-
8893(83)90025-1
Chang, W. C., Tzao, C., Hsu, H. H., Chang, H., Lo, C. P., and Chen, C. Y. (2005).
Isolated cryptococcal thoracic empyema with osteomyelitis of the rib in an
immunocompetent host. J. Infect. 51, e117–e119. doi: 10.1016/j.jinf.2004.10.011
Chaturvedi, V., and Chaturvedi, S. (2011). Cryptococcus gattii: a resurgent fungal
pathogen. Trends. Microbiol. 19, 564–571. doi: 10.1016/j.tim.2011.07.010
Chen, J., Varma, A., Diaz, M. R., Litvintseva, A. P., Wollenberg, K. K., and Kwon-
Chung, K. J. (2008).Cryptococcus neoformans strains and infection in apparently
immunocompetent patients, China. Emerging Infect. Dis. 14, 755–762. doi:
10.3201/eid1405.071312
Chen, Y. C., Chang, S. C., Shih, C. C., Hung, C. C., Luhbd, K. T., Pan, Y. S.,
et al. (2000). Clinical features and in vitro susceptibilities of two varieties of
Cryptococcus neoformans in Taiwan. Diagn. Microbiol. Infect. Dis. 36, 175–83.
doi: 10.1016/S0732-8893(99)00137-6
Ching, N., Lasky, J., Lazareff, J., Moore, T. B., and Nielsen, K. (2004). Enlarging
parietal mass with lytic skull lesion. Pediatr. Infect. Dis. J. 23, 589, 595–589, 596.
Chleboun, J., and Nade, S. (1977). Skeletal cryptococcosis. J. Bone Joint Surg. Am.
59, 509–514.
Cook, P. P. (2001). Successful treatment of cryptococcal osteomyelitis and
paraspinous abscess with fluconazole and flucytosine. South Med. J. 94,
936–938. doi: 10.1097/00007611-200109000-00024
Corral, J. E., Lima, S., Quezada, J., Samayoa, B., and Arathoon, E. (2011).
Cryptococcal osteomyelitis of the skull. Med. Mycol. 49, 667–671. doi: 10.3109/
13693786.2011.558124
Dounis, E., Giamarellou, H., Peppas, T., and Sfikakis, P. (1991). Skull, patella and
thigh cryptococcosis after a crashing injury of the temporal bone. J. Chemother.
3, 130–133.
Feng, X., Fu, X., Ling, B., Wang, L., Liao, W., and Yao, Z. (2013). Development of a
singleplex PCR assay for rapid identification and differentiation of Cryptococcus
neoformans var. grubii, Cryptococcus neoformans var. neoformans Cryptococcus
gattii, and hybrids. J. Clin. Microbiol. 51, 1920–1923. doi: 10.1128/JCM.00064-
13
Fialk, M. A., Marcove, R. C., and Armstrong, D. (1981). Cryptococcal bone disease:
a manifestation of disseminated cryptococcosis. Clin. Orthop. Relat. Res. 158,
219–223.
Flannery, M. T., Rivera, L., and Casanas, B. (2012). Cryptococcal neoformans
osteomyelitis—a case report and review of literature. Med. Case Rep. 3, 23–25.
Galloway, D. C., and Schochet, S. S. (1981). Cryptococcal skull granuloma. Case
report. J. Neurosurg. 54, 690–692. doi: 10.3171/jns.1981.54.5.0690
Geller, D. S., Pope, J. B., Thornhill, B. A., and Dorfman, H. D. (2009). Cryptococcal
pyarthrosis and sarcoidosis. Skeletal. Radiol. 38, 721–727. doi: 10.1007/s00256-
009-0691-0
Glynn, M. J., Duckworth, G., Ridge, J. A., Grange, W. J., and Gibbs, D. D. (1994).
Cryptococcal spondylitis: solitary infective bone lesions are not always tubercu-
lous. Rheumatology 33, 1085–1086. doi: 10.1093/rheumatology/33.11.1085
Goldshteyn, N., Zanchi, A., Cooke, K., and Agha, R. (2006). Cryptococcal
osteomyelitis of the humeral head initially diagnosed as avascular necrosis.
South. Med. J. 99, 1140–1141. doi: 10.1097/01.smj.0000224744.75040.13
Gould, P. R., and Gould, I. M. (1985). Cryptococcosis in Zimbabwe. Trans. R. Soc.
Trop. Med. Hyg. 79, 67–69. doi: 10.1016/0035-9203(85)90239-1
Govender, S., Ganpath, V., Charles, R.W., and Cooper, K. (1988). Localized osseous
cryptococcal infection. Report of 2 cases. Acta. Orthop. Scand. 59, 720–722. doi:
10.3109/17453678809149434
Gupta, S. K., Chhabra, R., Sharma, B. S., Das, A., and Khosla, V. K. (2003).
Vertebral cryptococcosis simulating tuberculosis. Br. J. Neurosurg. 17, 556–571.
doi: 10.1080/02688690310001626868
Gurevitz, O., Goldschmied-Reuven, A., Block, C., Kopolovic, J., Farfel, Z., and
Hassin, D. (1994). Cryptococcus neoformans vertebral osteomyelitis. J. Med. Vet.
Mycol. 32, 315–318. doi: 10.1080/02681219480000391
Hammerschlag, M. R., Domingo, J., Haller, J. O., and Papayanopulos, D. (1982).
Cryptococcal osteomyelitis: report of a case and a review of the literature. Clin.
Pediatr. 21, 109–112. doi: 10.1177/000992288202100208
Hansen, J., Slechta, E. S., Gates-Hollingsworth, M. A., Neary, B., Barker, A. P.,
Bauman, S., et al. (2013). Large-scale evaluation of the immuno-mycologics
lateral flow and enzyme-linked immunoassays for detection of cryptococcal
antigen in serum and cerebrospinal fluid. Clin. Vaccine Immunol. 20, 52–55. doi:
10.1128/CVI.00536-12
Frontiers in Microbiology | Infectious Diseases January 2015 | Volume 5 | Article 740 | 16
Zhou et al. Skeletal cryptococcosis 1977 to 2013
Harris, J. R., Lockhart, S. R., Debess, E., Marsden-Haug, N., Goldoft, M., Wohrle,
R., et al. (2011). Cryptococcus gattii in the United States: clinical aspects of
infection with an emerging pathogen. Clin. Infect. Dis. 53, 1188–1195. doi:
10.1093/cid/cir723
Hawkins, C., and Armstrong, D. (1984). Fungal infections in the immunocompro-
mised host. Clin. Haematol. 13, 599–630.
Hawkins, C., and Flaherty, J. P. (2007). Cryptococcal osteomyelitis of the fin-
ger complicated by meningitis. Infect. Dis. Clin. Pract. 15, 345–347. doi:
10.1097/IPC.0b013e3180315170
Heenan, P. J., and Dawkins, R. L. (1981). Cryptococcosis with multiple squamous
cell tumors associated with a T-cell defect. Cancer 47, 291–295.
Houda, B., Wafa, A., Zoubida, T. M., Mohamed, A., Mohamed, A., and
Hicham, H. (2011). Vertebrae cryptococcosis in an immunocompetent
patient—a case report. Pan. Afr. Med. J. 8, 42. doi: 10.4314/pamj.v8i1.
71158
Hummel, H., Stosiek, P., Lindner, R., and Bär, W. (1996). Osteomyelitis
from Cryptococcus neoformans. Mycoses 39, 94–96. doi: 10.1111/j.1439-
0507.1996.tb00512.x
Italiano, A., Yen, B. C., Rosenthal, S. A., and Rafii, M. (2001). Cryptococcal
osteomyelitis with septic arthritis. Orthopedics 24, 59–60.
Jacobson, M. E., Griesser, M. J., Paloski, M. D., and Mayerson, J. L. (2012).
Isolated Cryptococcus neoformans osteomyelitis of the proximal femur: a case
report and review of literature. Orthop. Surg. 4, 190–193. doi: 10.1111/j.1757-
7861.2012.00188.x
Jain, D., Najjar, M., Azher, Q., and Bachuwa, G. (2013). Cryptococcal sternal
osteomyelitis in a healthy woman: a review of Cryptococcus neoformans. BMJ
Case Rep. bcr2013009129. doi: 10.1136/bcr-2013-009129
Jain, K., Mruthyunjaya, and Ravishankar, R. (2011). Cryptococcal abscess and
osteomyelitis of the proximal phalanx of the hand. Indian J. Pathol. Microbiol.
54, 216–218. doi: 10.4103/0377-4929.77417
Jain, M., Sharma, S., and Jain, T. S. (1999). Cryptococcosis of thoracic vertebra
simulating tuberculosis: diagnosis by fine-needle aspiration biopsy cytology—a
case report. Diagn. Cytopathol. 20, 385–386.
Jou, H. J., Lee, F. T., Wang, M. N., Yang, P. Y., and Wang, N. P. (2011).
Bifocal cryptococcal osteomyelitis: management of a patient with concur-
rent femur and rib infections. Hip. Int. 21, 495–497. doi: 10.5301/HIP.2011.
8579
Klein, K. R., Hall, L., Deml, S. M., Rysavy, J. M., Wohlfiel, S. L., and Wengenack,
N. L. (2009). Identification of Cryptococcus gattii by use of L-canavanine
glycine bromothymol blue medium and DNA sequencing. J. Clin. Microbiol.
47, 3669–3672. doi: 10.1128/JCM.01072-09
Kontoyiannis, D. P., Peitsch, W. K., Reddy, B. T., Whimbey, E. E., Han, X. Y., Bodey,
G. P., et al. (2001). Cryptococcosis in patients with cancer. Clin. Infect. Dis. 32,
E145–E150. doi: 10.1086/320524
Kromminga, R., Staib, F., Thalmann, U., Jautzke, G., Seibold, M., Hochrein, H.,
et al. (1990). Osteomyelitis due to Cryptococcus neoformans in advanced age.
Case report and review of literature. Mycoses 33, 157–166.
Kumlin, U., Elmqvist, L. G., Granlund, M., Olsen, B., and Tärnvik, A. (1997). CD4
Lymphopeniaina patient with cryptococcal osteomyelitis. Scand. J. Infect. Dis.
29, 205–206. doi: 10.3109/00365549709035888
Levine, A. M., Meier, P., and Dorfman, H. D. (1985). Isolated cryptococ-
cus osteomyelitis of the humerus simulating a neoplasm of bone in a
patient with sarcoidosis. Case report 329. Skeletal Radiol. 14, 152–156. doi:
10.1007/BF00349754
Lie, K. W., Yu, Y. L., Cheng, I. K., Woo, E., and Wong, W. T. (1989). Cryptococcal
infection of the lumbar spine. J. R. Soc. Med. 82, 172–173.
Lindsley, M. D., Mekha, N., Baggett, H. C., Surinthong, Y., Autthateinchai, R.,
Sawatwong, P., et al. (2011). Evaluation of a newly developed lateral flow
immunoassay for the diagnosis of cryptococcosis. Clin. Infect. Dis. 53, 321–325.
doi: 10.1093/cid/cir379
Liu, P. Y. (1998). Cryptococcal osteomyelitis: case report and review. Diagn.
Microbiol. Infect. Dis. 30, 33–35. doi: 10.1016/S0732-8893(97)00190-9
Magid, D., and Smith, B. (1992). Cryptococcus neoformans osteomyelitis of the
clavicle. Orthopedics 15, 1068–1070.
Matsushita, T., and Suzuki, K. (1985). Spastic paraparesis due to cryptococcal
osteomyelitis. A case report. Clin. Orthop. Relat. Res. 196, 279–284.
Mauri, M., Catells, L., Ruiz, I., Vargas, V., and Guardia, J. (1997). Cryptococcal
arthritis as the primary form of human immunodeficiency syndrome. Enferm.
Infecc. Microbiol. Clin. 15, 560.
McGuire, D. T., Bick, S. M., andWestgarth-Taylor, T. (2011). Cryptococcoma of the
ilium in an immuno-competent child- a case report and review of the literature.
SA. Orthop. J. 10, 74–77.
McTaggart, L., Richardson, S. E., Seah, C., Hoang, L., Fothergill, A., and Zhang, S.
X. (2011). Rapid identification of Cryptococcus neoformans var. grubii, C. neo-
formans var. neoformans, and C. Gattii by use of rapid biochemical tests,
differential media, and DNA sequencing. J. Clin. Microbiol. 49, 2522–2527. doi:
10.1128/JCM.00502-11
Meredith, H. C., John, J. F. Jr., Rogers, C. I., Gooneratne, N., and Kreutner, A. Jr.
(1979). Case report 89. Skeletal Radiol. 4, 53–55. doi: 10.1007/BF00350599
Mitchell, T. G., and Perfect, J. R. (1995). Cryptococcosis in the era of AIDS—100
years after the discovery of Cryptococcus neoformans. Clin. Microbiol. Rev. 8,
515–548.
Negroni, R. (2012). Cryptococcosis. Clin. Dermatol. 30, 599–609. doi:
10.1016/j.clindermatol.2012.01.005
Noh, H. M., Kuszyk, B. S., and Fishman, E. K. (1999). Cryptococcoma of the
sacrum. Skeletal Radiol. 28, 49–51. doi: 10.1007/s002560050472
Perfect, J. R., Dismukes,W. E., Dromer, F., Goldman, D. L., Graybill, J. R., Hamill, R.
J., et al. (2010). Clinical practice guidelines for the management of cryptococcal
disease: 2010 update by the Infectious Diseases Society of America. Clin. Infect.
50, 291–322. doi: 10.1086/649858
Perfect, J. R., Durack, D. T., and Gallis, H. A. (1983). Cryptococcemia.Medicine 62,
98–109. doi: 10.1097/00005792-198303000-00003
Pirofski, L., and Casadevall, A. (1990). Mixed staphylococcal and cryptococcal
epidural abscess in a patient with AIDS. Rev. Infect. Dis. 12, 964–965. doi:
10.1093/clinids/12.5.964
Poliner, J. R., Wilkins, E. B., and Fernald, G. W. (1979). Localized osseous crypto-
coccosis. J. Pediatr. 94, 597–579. doi: 10.1016/S0022-3476(79)80020-7
Prendiville, S., Bielamowicz, S. A., Hawrych, A., and Deeb, Z. E. (2000). Isolated
cryptococcal sphenoid sinusitis with septicemia, meningitis, and subsequent
skull base osteomyelitis in an immunocompetent patient. Otolaryngol. Head
Neck Surg. 123, 277–279. doi: 10.1067/mhn.2000.104777
Qadir, I., Ali, F., Malik, U. Z., and Umer, M. (2011). Isolated cryptococcal
osteomyelitis in an immunocompetent patient. J. Infect. Dev. Ctries. 5, 669–673.
Raftopoulos, I., Meller, J. L., Harris, V., and Reyes, H. M. (1998). Cryptococcal
rib osteomyelitis in a pediatric patient. J. Pediatr. Surg. 33, 771–773. doi:
10.1016/S0022-3468(98)90216-0
Ramkillawan, Y., Dawood, H., and Ferreira, N. (2013). Isolate cryptococcal
osteomyelitis in an immune-competent patient host: a case report. Int. J. Infect.
Dis. 17, e1229–e1231. doi: 10.1016/j.ijid.2013.04.013
Reinig, J. W., Hungerford, G. D., Mohrmann, M. E., and Vera, C. L. (1984). Case
report 268. Diagnosis: cryptococcal osteomyelitis of the calvaria. Skeletal Radiol.
11, 221–223. doi: 10.1007/BF00349499
Ricciardi, D. D., Sepkowitz, D. V., Berkowitz, L. B., Bienenstock, H., and Maslow,
M. (1986). Cryptococcal arthritis in a patient with acquired immune defi-
ciency syndrome. Case report and review of the literature. J. Rheumatol. 13,
455–458.
Saeed, M. U., Dacuycuy, M. A., and Kennedy, D. J. (2009). Cryptococcal epidural
abscess with bone involvement: case report and review of literature. Infect. Dis.
Clin. Pract. 17, 193–195. doi: 10.1097/IPC.0b013e3181812c14
Schmidt, D. M., Sercarz, J. A., Kevorkian, K. F., and Canalis, R. F. (1995).
Cryptococcosis presenting as a neck mass. Ann. Otol. Rhinol. Larygol. 104,
711–714. doi: 10.1177/000348949510400908
Shaff, M. I., Berger, J. L., and Green, N. E. (1982). Cryptococcal osteomyelitis,
pulmonary sarcoidosis, and tuberculosis in a single patient. South. Med. J. 75,
225–226. doi: 10.1097/00007611-198202000-00026
Singh, N., Rihs, J., Gaywoski, T., and Yu, V. (1994). Cutaneous cryptococcosis mim-
icking bacterial cellulitis in a liver transplant recipient: case report and review in
solid organ transplant recipients. Clin. Transpl. 8, 365–368.
Singh, R., and Xess, I. (2010). Multiple osseous involvements in a case of dis-
seminated cryptococcosis. Indian J. Orthop. 44, 336–338. doi: 10.4103/0019-
5413.65158
Sinnott, J. T., and Holt, D. A. (1989). Cryptococcal pyarthrosis complicating gouty
arthritis. South. Med. J. 82, 1555–1556. doi: 10.1097/00007611-198912000-
00024
Sorensen, R. U., Boehm, K. D., Kaplan, D., and Berger, M. (1992).
Cryptococcal osteomyelitis and cellular immunodeficiency associated with
interleukin-2 deficiency. J. Pediatr. 121, 873–879. doi: 10.1016/S0022-3476(05)
80331-2
www.frontiersin.org January 2015 | Volume 5 | Article 740 | 17
Zhou et al. Skeletal cryptococcosis 1977 to 2013
Speed, B., and Dunt, D. (1995). Clinical and host differences between infections
with the two varieties of Cryptococcus neoformans. Clin. Infect. Dis. 21, 28–34.
doi: 10.1093/clinids/21.1.28
Stead, K. J., Klugman, K. P., Painter,M. L., and Koornhof, H. J. (1988). Septic arthri-
tis due to Cryptococcus neoformans. J. Infect. 17, 139–145. doi: 10.1016/S0163-
4453(88)91683-0
Thompson, G. R., Wiederhold, N. P., Fothergill, A. W., Vallor, A. C.,
Wickes, B. L., and Patterson, T. F. (2009). Antifungal susceptibilities
among different serotypes of Cryptococcus gattii and Cryptococcus neo-
formans. Antimicrob. Agents. Chemother. 53, 309–311. doi: 10.1128/AAC.
01216-08
Ueda, Y., Roessner, A., Edel, G., Wuisman, P., Erlemann, R., and Böcker,
W. (1992). Case report 699. Primary localized skeletal cryptococcosis
(torulosis) of the right tibia at its proximal end. Skeletal Radiol. 21,
117–119.
Venkatachala, S., Naik, D. R., Shanthakumari, S., and Jayaraman, A. (2010).
Acquired immunodeficiency syndrome presenting as marrow cryptococ-
cosis. Indian J. Pathol. Microbiol. 53, 904–906. doi: 10.4103/0377-4929.
72069
Wildstein, M. S., Martin, S. M., and Glaser, J. A. (2005). Cryptococcal
osteomyelitis in a 20-year-old male with sarcoidosis. Spine J. 5, 467–470. doi:
10.1016/j.spinee.2004.12.002
Witte, D. A., Chen, I., Brady, J., Ramzy, I., Truong, L. D., and Ostrowski, M. L.
(2000). Cryptococcal osteomyelitis. Report of a case with aspiration biopsy of a
humeral lesion with radiologic features of malignancy. Acta Cytol. 44, 815–818.
doi: 10.1159/000328567
Wood, L., andMiedzinski, L. (1996). Skeletal cryptococcosis: case report and review
of the literature. Can. J. Infect. Dis. 7, 125–132.
Yu, J. Q., Tang, K. J., Xu, B. L., Xie, C. M., and Light, R. W. (2012). Pulmonary
cryptococcosis in non-AIDS patients. Infect. Dis. 16, 531–539. doi: 10.1016/j.
bjid.2012.07.004
Zach, T. L., and Penn, R. G. (1986). Localized cryptococcal osteomyeli-
tis in an immunocompetent host. Pediatr. Infect. Dis. 5, 601–603. doi:
10.1097/00006454-198609000-00029
Zanelli, G., Sansoni, A., Ricciardi, B., Ciacci, C., and Cellesi, C. (2001). Muscular-
skeletal cryptococcosis in a patient with idiopathic CD4+ lymphopenia.
Mycopathologia 149, 137–139. doi: 10.1023/A:1007271822625
Zhang, Y., Yu, Y. S., Tang, Z. H., and Zang, G. Q. (2012). Cryptococcal osteomyeli-
tis of the scapula and rib in an immunocompetent patient. Med. Mycol. 50,
751–755. doi: 10.3109/13693786.2012.670277
Zhou, H. X., Ning, G. Z., Feng, S. Q., Jia, H. W., Liu, Y., Feng, H. Y., et al. (2013).
Cryptococcosis of lumbar vertebra in a patient with rheumatoid arthritis and
scleroderma: case report and literature review. BMC Infect. Dis. 13:128. doi:
10.1186/1471-2334-13-128
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Received: 29 August 2014; accepted: 05 December 2014; published online: 14 January
2015.
Citation: Zhou H-X, Lu L, Chu T, Wang T, Cao D, Li F, Ning G and Feng S (2015)
Skeletal cryptococcosis from 1977 to 2013. Front. Microbiol. 5:740. doi: 10.3389/fmicb.
2014.00740
This article was submitted to Infectious Diseases, a section of the journal Frontiers in
Microbiology.
Copyright © 2015 Zhou, Lu, Chu, Wang, Cao, Li, Ning and Feng. This is an open-
access article distributed under the terms of the Creative Commons Attribution License
(CC BY). The use, distribution or reproduction in other forums is permitted, provided
the original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Microbiology | Infectious Diseases January 2015 | Volume 5 | Article 740 | 18
